Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients
Authors
Keywords
-
Journal
CANCER
Volume 128, Issue 5, Pages 995-1003
Publisher
Wiley
Online
2021-12-08
DOI
10.1002/cncr.34019
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- Japanese gastric cancer treatment guidelines 2018 (5th edition)
- (2020) Gastric Cancer
- The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.
- (2020) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.
- (2020) Kohei Shitara et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
- (2020) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
- (2020) N. Boku et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
- (2018) In Sil Choi et al. PLoS One
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm
- (2017) Akira Sawaki et al. Gastric Cancer
- Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world
- (2017) Atsuo Takashima et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea
- (2017) Gebra Cuyun Carter et al. Cancer Research and Treatment
- Examining the gastric cancer survival gap between Asians and whites in the United States
- (2016) Hongbin Jin et al. Gastric Cancer
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started